Market Place
Sourcing Support
Faron Pharmaceuticals Ltd: Registration of Treasury Shares
11 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Holdings in Company
11 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Holding(s) in Company
10 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals LTD: Holding(s) in Company
08 Jun 2026 //
ACCESSWIRE
Faron Pharma Receives Nasdaq Helsinki Disciplinary Decision
05 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals: Holdings in Company Disclosed
04 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals LTD: Holding(S) In Company
01 Jun 2026 //
ACCESSWIRE
Faron Pharmaceuticals Discloses Holdings in Company
28 May 2026 //
ACCESSWIRE
Faron Pharmaceuticals Details Special Bond Rights
28 May 2026 //
ACCESSWIRE
Faron Pharma Issues Major Shareholding Notification
18 May 2026 //
PHARMIWEB
Faron To Unveil BEXMAB Data In HR-MDS At EHA 2026
13 May 2026 //
ACCESSWIRE
Faron Pharmaceuticals Terminates Liquidity Provision Service
06 May 2026 //
PHARMIWEB
Faron Pharma Ltd: Key Company Holdings
05 May 2026 //
ACCESSWIRE
Faron Pharma Announces Directorate Appointment
05 May 2026 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Results Of The Annual General Meeting
04 May 2026 //
PHARMIWEB
Faron Pharmaceuticals Ltd: Holding(s) In Company
22 Apr 2026 //
PHARMIWEB
Faron Collaborates With Parexel For Phase IIb BEXERA Trial
16 Apr 2026 //
PHARMIWEB
Faron Pharma Ltd: Holdings Overview
16 Apr 2026 //
PHARMIWEB
Faron Pharma Issues AGM Notice
10 Apr 2026 //
PHARMIWEB
Faron Pharma Ltd: Director Dealing Update
31 Mar 2026 //
PHARMIWEB
Faron Pharma Appoints New CTO For Late-Stage Development
26 Mar 2026 //
PHARMIWEB
Faron Pharmaceuticals Ltd: Director Dealing
19 Mar 2026 //
PHARMIWEB
Faron Pharma Ltd: Key Company Holdings
12 Mar 2026 //
ACCESSWIRE
Faron Pharma Adjusts 2026 Financial Calendar And AGM Date
09 Mar 2026 //
ACCESSWIRE
Faron Pharma Releases 2025 Annual Report
04 Mar 2026 //
PHARMIWEB
Faron Releases 2025 Financial Statements
04 Mar 2026 //
PHARMIWEB
Faron Pharma: Extraordinary General Meeting Results
02 Mar 2026 //
PHARMIWEB
Faron, City Of Hope Developing Phase II Trial For Bexmarilimab
02 Mar 2026 //
PHARMIWEB
Faron Secures Bexmarilimab Poster at BSH 2026 Meeting
23 Feb 2026 //
PHARMIWEB
Faron Pharma: Extraordinary General Meeting Notice
09 Feb 2026 //
PHARMIWEB
Immunotherapy Review Spotlights Clever-1 Inhibition
29 Jan 2026 //
PHARMIWEB
Faron Expands Bexmarilimab Program With Phase I/II Trial
27 Jan 2026 //
ACCESSWIRE
Faron Collaborates With Institute For Cancer Research On BLAZE
22 Dec 2025 //
PHARMIWEB
Faron Pharma Announces Nomination Board Composition
17 Dec 2025 //
PHARMIWEB
Faron Issues Second €10M Tranche of Convertible Bonds
11 Dec 2025 //
PHARMIWEB
Faron Unveils Updated BEXMAB Data in High-Risk MDS at ASH 2025
08 Dec 2025 //
PHARMIWEB
Faron Pharma Ltd: Key Company Holdings
04 Dec 2025 //
PHARMIWEB
Faron Pharma Grants Stock Options
02 Dec 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Appointment Of CFO
01 Dec 2025 //
PHARMIWEB
Faron`s 2026 Financial Calendar
27 Nov 2025 //
PHARMIWEB
Faron to Issue Second €10M Convertible Bonds
24 Nov 2025 //
PHARMIWEB
Faron Reveals 2 Bexmarilimab Abstracts Accepted At ASH 2025
04 Nov 2025 //
PHARMIWEB
Faron Advances Bexmab To FDA Registrational Trial Post Phase 2
03 Nov 2025 //
PHARMIWEB
Faron Pharmaceuticals Ltd: Holding(S) In Company
21 Oct 2025 //
ACCESSWIRE
BEXMAB Ph1/2 Data at ESMO 2025 Strengthens Bexmarilimab Profile
20 Oct 2025 //
ACCESSWIRE
Faron Pharma: Exercise of Option, Director Dealings, Equity Issue
19 Sep 2025 //
ACCESSWIRE
Faron Pharmaceuticals: Half-Year Financial Results Jan-Jun 2025
12 Sep 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd Reports Half-Year Financial Results
27 Aug 2025 //
PHARMAWEB
Faron Pharmaceuticals Announces Half-Year Financial Results
19 Aug 2025 //
ACCESSWIRE
Faron Gets New US Patent for Bexmarilimab in Cancer Treatment
08 Aug 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Company Holdings
08 Aug 2025 //
ACCESSWIRE
Faron to Present Updated Bexmab Data to Fda, Showing 43%
06 Aug 2025 //
ACCESSWIRE
Faron`s Bexmarilimab Studies Accepted for Oral Presentation
09 Jul 2025 //
ACCESSWIRE
Faron Study Highlights sClever-1 as Immune Blocker in Cancer
03 Jul 2025 //
INDPHARMAPOST
Faron Pharmaceuticals Ltd: Director Dealing
02 Jul 2025 //
ACCESSWIRE
Faron Pharmaceuticals updates Phase II data at EHA 2025
12 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Director Donates Shares to Foundation
05 Jun 2025 //
PHARMAWEB
Faron Pharmaceuticals: Director Donates Shares to Foundation
05 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Presents Phase II Data at ASCO 2025
02 Jun 2025 //
ACCESSWIRE
Faron Publishes Phase I BEXMAB Study Data in Lancet Haematology
30 May 2025 //
ACCESSWIRE
